Contraception
Volume 82, Issue 2 , Pages 174-177 , August 2010

Effect of depot medroxyprogesterone acetate on postpartum depression

  • Rita Tsai
    • ,
  • Jonathan Schaffir

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, 2831 Cramblett Hall, 456 West 10th Ave., Columbus, OH 43210, USA. Tel.: +1 614 293 3069; fax: +1 614 293 5877.

Received 1 December 2009 ,Revised 16 February 2010 ,Accepted 3 March 2010.

References 

  1. Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49:186–190
  2. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study.. Lancet. 1991;338:833–838
  3. Stanford JL, Thomas DB. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49:191–195
  4. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception. 1992;45:299–312
  5. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception. 1998;57:315–324
  6. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA. 1995;273:799–804
  7. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. 2000;151:396–403
  8. Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception. 2000;61:385–390
  9. O'Hara MW, Zekoski EM, Philipps LH, Wright EJ. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol. 1990;99:3
  10. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry. 1998;59(Suppl 2):53
  11. Murray L, Fiori-Cowley A, Hooper R, Cooper P. The impact of postnatal depression and associated adversity on early mother–infant interactions and later infant outcome. Child Dev. 1996;67:2512
  12. Stein A, Gath DH, Bucher J, et al. The relationship between post-natal depression and mother–child interaction. Br J Psychiatry. 1991;158:46
  13. Beck CT. A meta-analysis of the relationship between postpartum depression and infant temperament. Nurs Res. 1996;45:225
  14. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Women Ment Health. 2005;8:77
  15. Schiff MA, Grossman DC. Adverse perinatal outcomes and risk for postpartum suicide attempt in Washington state, 1987–2001. Pediatrics. 2006;118:e669
  16. Lawrie TA, Herxheimer A, Dalton K. Oestrogens and progestogens for preventing and treating postnatal depression. Cochrane Database Syst Rev. 2000;CD001690
  17. Granger AC, Underwood MR. Review of the role of progesterone in the management of postnatal mood disorders. J Psychosom Obstet Gynecol. 2001;22:49–55
  18. Karuppaswamy J, Vlies R. The benefit of oestrogens and progestogens in postnatal depression. J Obstet Gynaecol. 2003;23:341–346
  19. Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomized placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998;105:1082
  20. Stevens-Simon C, Kelly L, Wallis J. The timing of Norplant insertion and postpartum depression in teenagers. J Adolesc Health. 2000;26:408–413
  21. Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York (NY): Thomson Reuters; 2008;
  22. Murray L, Carothers AD. The validation of the Edinburgh Post-natal Depression Scale on a community sample. Br J Psychiatry. 1990;157:288
  23. Schaper AM, Rooney BL, Kay NR, Silva PD. Use of the Edinburgh Postnatal Depression Scale to identify postpartum depression in a clinical setting. J Reprod Med. 1994;39:620
  24. Glaze R, Cox JL. Validation of a computerized version of the 10-item (self-rating) Edinburgh Postnatal Depression Scale. J Affect Disord. 1991;22:73
  25. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782–786
  26. O'Hara MW. Postpartum depression: what we know. J Clin Psychol. 2009;65:1258–1269
  27. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. AHRQ Evidence Report No. 1193, 2005.

☆ This study was performed without funding.

PII: S0010-7824(10)00094-6

doi: 10.1016/j.contraception.2010.03.004

Contraception
Volume 82, Issue 2 , Pages 174-177 , August 2010

Article Tools